Document Detail


Thalidomide for treatment of severe intestinal bleeding.
MedLine Citation:
PMID:  15016759     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Apart from its anti-inflammatory activity, which has been used for the treatment of active Crohn's disease, thalidomide is also a potent inhibitor of angiogenesis. We therefore studied the effect of thalidomide in six patients with severe recurrent intestinal bleeding refractory to standard treatment (three patients with Crohn's disease (CD), three patients with obscure intestinal bleeding; mean of 56 blood transfusions within the last 24 months). Bleeding stopped within two weeks after the start of thalidomide in all patients. Haemoglobin normalised without further transfusions for the whole observation period (mean follow up 33 months) while patients needed a mean of 2.2 (CD) and 3.1 (obscure bleeding) blood units/month in the 12 months before treatment. After three months of thalidomide therapy, serum levels of vascular endothelial growth factor were strongly suppressed compared with pretreatment levels. (CD 818 (82) v 129 (86) pg/ml; obscure bleeding 264 (68) v 50 (25) pg/ml). All six patients reported transient fatigue. Peripheral neuropathy was observed in one patient with CD after nine months and was reversible after lowering the dose to 100 mg daily. These results indicate that thalidomide might be useful for patients with otherwise refractory intestinal bleeding.
Authors:
J Bauditz; G Schachschal; S Wedel; H Lochs
Related Documents :
17961169 - Factor viii inhibitor bypassing activity (feiba) - addressing safety issues.
12695459 - Deaths associated with platelet glycoprotein iib/iiia inhibitor treatment.
12709699 - Prophylactic clip application does not decrease delayed bleeding after colonoscopic pol...
8530229 - Endoscopic adrenaline injection in treatment of bleeding peptic ulcers.
11742159 - Effective use of argon plasma coagulation in the treatment of severe radiation proctitis.
18218579 - Fatal cytomegalovirus gastrointestinal disease in an infant with wiskott-aldrich syndrome.
9226289 - Detection of patients at risk for recurrence of atrial fibrillation after successful el...
12211679 - Deterioration of long-term clinical results after the elmslie-trillat procedure for dis...
12112719 - Reduction in variability of acetabular cup abduction using computer assisted surgery: a...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Gut     Volume:  53     ISSN:  0017-5749     ISO Abbreviation:  Gut     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-03-12     Completed Date:  2004-04-23     Revised Date:  2013-06-09    
Medline Journal Info:
Nlm Unique ID:  2985108R     Medline TA:  Gut     Country:  England    
Other Details:
Languages:  eng     Pagination:  609-12     Citation Subset:  AIM; IM    
Affiliation:
Charité University Hospital, IVth Department of Medicine, Berlin, Germany. juergen.bauditz@charite.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angiogenesis Inhibitors / therapeutic use*
Crohn Disease / complications
Female
Gastrointestinal Hemorrhage / blood,  drug therapy*,  etiology
Humans
Male
Middle Aged
Recurrence
Thalidomide / therapeutic use*
Vascular Endothelial Growth Factor A / blood
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Vascular Endothelial Growth Factor A; 50-35-1/Thalidomide
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetics of liver disease: immunogenetics and disease pathogenesis.
Next Document:  A novel TEAD1 mutation is the causative allele in Sveinsson's chorioretinal atrophy (helicoid peripa...